Article Details

Xencor Presents Clinical Data from the Phase 1 Study of Tidutamab in Neuroendocrine ...

Retrieved on: 2021-11-04 14:43:10

Tags for this article:

Click the tags to see associated articles and topics

Xencor Presents Clinical Data from the Phase 1 Study of Tidutamab in Neuroendocrine .... View article details on hiswai:

Excerpt

(NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and ...

Article found on: pipelinereview.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up